Developer of genetic analysis tools intended to be used for the research and diagnostic markets.
Developer of genetic analysis tools intended to be used for the research and diagnostic markets.
Diagnostic Equipment📍 San Diego, CAFounded 2017
Current Valuation
$1.0B
as of 2024-Q3
UNICORN
QL Price
$685.25M
-34% vs last round
QuantLogix's current estimate for Element Biosciences, published 2026-09-27 — below the last disclosed round of $1.0B (2024-Q3).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$1.0B
2024-Q3
weight 0.25
Secondary market print
$530.4M
2026-06-27
weight 0.58
How this price has held up
No round has priced for Element Biosciences since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Element Biosciences, 2026-09-27 (c02a01dd3d95a9a6).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Element Biosciences going public?
No. Element Biosciences is private and has not filed to go public. There is no S-1 on file.
What is Element Biosciences' valuation in 2026?
Element Biosciences is valued at $1.0B as of 2024-Q3, set by its Series D ($277M, Jul 2024). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Element Biosciences filed an S-1?
No public S-1 is on file for Element Biosciences.
How much has Element Biosciences raised?
Element Biosciences has raised $683.3M in total, most recently a Series D of $277M in Jul 2024.
Is Element Biosciences publicly traded — can you buy Element Biosciences stock?
No. Element Biosciences is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Element Biosciences on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2017
HQ
San Diego, CA
Employees
440
Total Raised
$683.3M
Last Round
Series D — $277M (Jul 2024)
IPO Status
private
Fundraising Status
Series D · $277M · 2y 2mo ago
privateTotal raised $683.3M
Secondary Market
Implied price / share
$4
Last round price / share
$7.84
vs last round
-49.0%
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series D
$277M
Jul 2024
—
$1.0B
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Element Biosciences — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-27. Re-checked weekly.
Talent Signal
Hiring trend
▶ Hiring steady
+7% vs 2026-08
Open roles
16
via greenhouse
Product-build share
56%
engineering, research, product, design
Trajectory
steady
product-led hiring — 56% of open roles build product; the rest are go-to-market and G&A.
Counted from Element Biosciences's live job board as of 2026-09-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
BiotechnologyGeneticsHealth Diagnostics
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2024-Q3. Refreshed quarterly.